Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Melatonin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurim Wins EU Approval for Pediatric Melatonin (Slenyto) in ADHD
Details : Slenyto is a prolonged-release formulation of melatonin, which is indicated for the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD).
Product Name : Slenyto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Melatonin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurim Receives Positive CHMP Opinion for Slenyto® in Children with Neurogenic Insomnia
Details : Slenyto (melatonin) is an approved melatonin receptor agonist, which is currently being evaluated for the treatment of insomnia in children with neurogenetic disorders.
Product Name : Slenyto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2024